Lodonal (naltrexone low dose oral) / Immune Therap, Statera BioPharma 
Welcome,         Profile    Billing    Logout  
 59 Diseases   17 Trials   17 Trials   538 News 


«12345678»
  • ||||||||||  Lodonal (naltrexone low dose oral) / Immune Therap, Statera BioPharma
    Journal:  Low-Dose Naltrexone (LDN) for Chronic Pain at a Single Institution: A Case Series. (Pubmed Central) -  Jun 20, 2023   
    The diagnosis of spondylosis was more often associated with a lack of response to LDN than any other diagnosis. Patients may need to have a trial of several weeks before analgesic effects are seen with LDN.
  • ||||||||||  Lodonal (naltrexone low dose oral) / Immune Therap, Statera BioPharma
    Review, Journal:  Low Dose Naltrexone's Utility for Non-Cancer Centralized Pain Conditions - A Scoping Review. (Pubmed Central) -  Jun 11, 2023   
    Upon review of the current available published studies, it is apparent that further high-quality, well-powered RCTs need to be conducted in order to establish efficacy, standardization for dosing, and determine response times. In summary, LDN continues to offer promising results in the management of pain and other distressing symptoms in patients with chronic centralized pain conditions.
  • ||||||||||  Lodonal (naltrexone low dose oral) / Immune Therap, Statera BioPharma
    Review, Journal:  Low-Dose Naltrexone in Rheumatological Diseases. (Pubmed Central) -  May 24, 2023   
    This review shows that LDN is a promising and safe therapy to be used in some rheumatic disease. However, the data is limited and needs to be reproduced in larger studies.
  • ||||||||||  Lodonal (naltrexone low dose oral) / Immune Therap, Statera BioPharma
    Enrollment open:  Low Dose Naltrexone for Pain in Patients With HIV (clinicaltrials.gov) -  May 3, 2023   
    P4,  N=60, Recruiting, 
    In the second experiment, we injected LDN (1 Not yet recruiting --> Recruiting
  • ||||||||||  Lodonal (naltrexone low dose oral) / Immune Therap, Statera BioPharma
    Trial completion, Enrollment change, Trial completion date:  IC PaIN Trial: Interstitial Cystitis Pain Improvement With Naltrexone (clinicaltrials.gov) -  Apr 28, 2023   
    P4,  N=2, Completed, 
    Not yet recruiting --> Recruiting Recruiting --> Completed | N=44 --> 2 | Trial completion date: Jun 2023 --> Feb 2023
  • ||||||||||  Lodonal (naltrexone low dose oral) / Immune Therap, Statera BioPharma
    Journal:  Low-dose naltrexone (LDN): consumption trend in Brazilian capitals and the Federal District, 2014-2020 (Pubmed Central) -  Mar 13, 2023   
    Increasing dispensation of LDN was observed in 55.6% of the capitals, being stationary in 44.4%, with no decreasing coefficients. Despite the limited evidence regarding LDN pharmacotherapy and its off-label prescription, the data show that prescription, dispensing, and consumption have been on the increase in Brazil, with emphasis on the central-south regions of the country.
  • ||||||||||  Lodonal (naltrexone low dose oral) / Immune Therap, Statera BioPharma
    Journal:  Recalcitrant cases of Hailey-Hailey disease successfully managed with low-dose naltrexone. (Pubmed Central) -  Feb 27, 2023   
    Despite the limited evidence regarding LDN pharmacotherapy and its off-label prescription, the data show that prescription, dispensing, and consumption have been on the increase in Brazil, with emphasis on the central-south regions of the country. No abstract available
  • ||||||||||  Trial completion date, Trial primary completion date:  Psychobiological Mechanisms Underlying Chronic Pain (clinicaltrials.gov) -  Feb 14, 2023   
    P=N/A,  N=100, Recruiting, 
    No abstract available Trial completion date: Dec 2022 --> Aug 2023 | Trial primary completion date: Dec 2022 --> Mar 2023
  • ||||||||||  Lodonal (naltrexone low dose oral) / Immune Therap, Statera BioPharma
    Pharmacology in Pain Management Workshop () -  Feb 3, 2023 - Abstract #APS2023APS_76;    
    We will explore the complex interplay of genetic variation in pharmacokinetic and pharmacodynamic pathways affecting opioid efficacy, and discuss the challenges opioid weaning and appropriate strategies through opioid substitution.We will also take a fascinating look at how food can be medicine and where dietitians play a vital role in pain management and its application in clinical practice. There will be opportunities for questions and networking with peers, so that current evidence-based knowledge can be optimised and translated in everyday practice.
  • ||||||||||  Lodonal (naltrexone low dose oral) / Immune Therap, Statera BioPharma
    Trial completion date, Trial primary completion date:  The Effects of Low Dose Naltrexone (LDN) on Diseases of Aging (clinicaltrials.gov) -  Jan 25, 2023   
    P=N/A,  N=2500, Recruiting, 
    There will be opportunities for questions and networking with peers, so that current evidence-based knowledge can be optimised and translated in everyday practice. Trial completion date: Aug 2022 --> Mar 2023 | Trial primary completion date: Aug 2022 --> Mar 2023
  • ||||||||||  Lodonal (naltrexone low dose oral) / Immune Therap, Statera BioPharma
    Trial completion, Enrollment change:  Pilot Study Into LDN and NAD+ for Treatment of Patients With Post-COVID-19 Syndrome (clinicaltrials.gov) -  Jan 25, 2023   
    P2,  N=36, Completed, 
    Trial completion date: Aug 2022 --> Mar 2023 | Trial primary completion date: Aug 2022 --> Mar 2023 Active, not recruiting --> Completed | N=60 --> 36
  • ||||||||||  Lodonal (naltrexone low dose oral) / Immune Therap, Statera BioPharma
    Trial completion:  COLTREXONE: Impact of Colchicine and Low-dose Naltrexone on COVID-19 (clinicaltrials.gov) -  Jan 12, 2023   
    P2,  N=142, Completed, 
    Active, not recruiting --> Completed | N=60 --> 36 Enrolling by invitation --> Completed
  • ||||||||||  naltrexone / Generic mfg.
    Trial completion, Trial completion date:  Fibromyalgia and Naltrexone: The FINAL Study (clinicaltrials.gov) -  Dec 29, 2022   
    P2,  N=99, Completed, 
    Enrolling by invitation --> Completed Recruiting --> Completed | Trial completion date: Jun 2023 --> Dec 2022
  • ||||||||||  Lodonal (naltrexone low dose oral) / Immune Therap, Statera BioPharma
    Trial completion date, Trial primary completion date:  LoDoNaVasc: Low Dose Naltrexone to Improve Physical Health in Patients With Vasculitis (clinicaltrials.gov) -  Dec 16, 2022   
    P2,  N=36, Recruiting, 
    Recruiting --> Completed | Trial completion date: Jun 2023 --> Dec 2022 Trial completion date: Dec 2022 --> Dec 2023 | Trial primary completion date: Dec 2022 --> Dec 2023
  • ||||||||||  Lodonal (naltrexone low dose oral) / Immune Therap, Statera BioPharma
    Trial completion date, Trial initiation date, Trial primary completion date:  Low-dose Naltrexone for Post-COVID Fatigue Syndrome (clinicaltrials.gov) -  Dec 9, 2022   
    P2,  N=160, Not yet recruiting, 
    Trial completion date: Dec 2022 --> Dec 2023 | Trial primary completion date: Dec 2022 --> Dec 2023 Trial completion date: Dec 2022 --> Feb 2024 | Initiation date: Jul 2022 --> Mar 2023 | Trial primary completion date: Dec 2022 --> Feb 2024
  • ||||||||||  Lodonal (naltrexone low dose oral) / Immune Therap, Statera BioPharma
    Review, Journal:  A Comprehensive Review: Chronic Pain Sequelae in the Presence of Ehlers-Danlos Syndrome. (Pubmed Central) -  Nov 27, 2022   
    Newer therapies that have shown promising effects for both decreasing pain and increasing quality of life include physical/occupational therapy, transcutaneous electrical nerve stimulation units, trigger point injections, low-dose naltrexone, and laser therapy...Treatment options should be structured based on the specific type of pain pathology and presenting symptoms of each patient and their comorbidities. Future research should attempt to prioritize larger sample sizes, clear definitions of EDS subtypes, randomized trials for treatment efficacy, and more studies dedicated to non-musculoskeletal forms of pain.
  • ||||||||||  Lodonal (naltrexone low dose oral) / Immune Therap, Statera BioPharma
    Journal:  Low-dose naltrexone reduced anxiety in persons with multiple sclerosis during the COVID-19 pandemic. (Pubmed Central) -  Nov 17, 2022   
    Utilizing mailed surveys, self-reported anxiety and depression scores were found to be significantly lower for PwMS who were prescribed LDN either alone or as an adjuvant to a standard disease modifying therapy (DMT) in comparison to those on oral disease-modifying therapies (DMTs). The data suggest that the non-toxic, inexpensive biotherapeutic may be beneficial in lessening anxiety.
  • ||||||||||  Lodonal (naltrexone low dose oral) / Immune Therap, Statera BioPharma
    Preclinical, Journal:  Antinociceptive Effect of Ultra-Low Dose Naltrexone in A Pre-Clinical Model of Postoperative Orofacial Pain. (Pubmed Central) -  Nov 8, 2022   
    Stimulation of macrophages with LPS resulted in increase of nitric oxide, IL-1β and CXCL-2 levels which were reduced by NTX. Altogether, these results provide evidence for an antinociceptive effect of ULDN in postoperative orofacial pain and suggest that blockade of TLR4 and downstream signaling pathway contribute to its effect.
  • ||||||||||  Lodonal (naltrexone low dose oral) / Immune Therap, Statera BioPharma
    Review, Journal:  Novel Therapies for Centralized Pain: a Brief Review. (Pubmed Central) -  Nov 8, 2022   
    This is successfully conducted through patient-physician communication as this is a highly complex and personalized pain category. Our examination shows that while physicians have many options with proven success, there is a need for studies with longitudinal and larger patient populations to better articulate treatment guidelines.
  • ||||||||||  Lodonal (naltrexone low dose oral) / Immune Therap, Statera BioPharma
    Enrollment change, Trial termination, Combination therapy:  Low-Dose Naltrexone in Combination With Standard Treatment in Women With Endometriosis (clinicaltrials.gov) -  Nov 3, 2022   
    P3,  N=9, Terminated, 
    Our examination shows that while physicians have many options with proven success, there is a need for studies with longitudinal and larger patient populations to better articulate treatment guidelines. N=160 --> 9 | Recruiting --> Terminated; Original PI left institution, lack of funding to continue
  • ||||||||||  Lodonal (naltrexone low dose oral) / Immune Therap, Statera BioPharma
    Trial completion date, Trial initiation date, Trial primary completion date:  Low Dose Naltrexone Use in Patients With POTS (clinicaltrials.gov) -  Oct 25, 2022   
    P4,  N=80, Not yet recruiting, 
    This may help patients who are reluctant to or have some contraindication for interventional therapies. Trial completion date: Dec 2025 --> Dec 2026 | Initiation date: Jun 2022 --> Feb 2023 | Trial primary completion date: Jun 2025 --> Jun 2026
  • ||||||||||  Lodonal (naltrexone low dose oral) / Immune Therap, Statera BioPharma
    Enrollment change, Trial withdrawal:  Pilot Study Into the Use of Metformin and LDN for Patients With COVID-19 (clinicaltrials.gov) -  Oct 4, 2022   
    P2,  N=0, Withdrawn, 
    This study may provide evidence of the benefit of LDN for the groups in whom conventional anti-depressants are ineffective and lead the way for translation into clinical practice. N=80 --> 0 | Not yet recruiting --> Withdrawn